- Conditions
- Breast Cancer
- Interventions
- [68Ga]Ga-NeoB, [177Lu]Lu-NeoB, Ribociclib, Fulvestrant, Goserelin
- Drug · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2032
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 169–192
of 327
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Stroke
- Interventions
- Hybrid combination of physical therapy and powered exoskeleton, Powered Exoskeleton Only, Physical Therapy only
- Other
- Lead sponsor
- Loma Linda University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Loma Linda, California
- Conditions
- Carcinoma, Hepatocellular, Liver Neoplasms
- Interventions
- Mailed Outreach Invitation, Mailed Outreach Invitation and Patient Navigation
- Other
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 1,800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Solid Tumour
- Interventions
- Savolitinib, Itraconazole
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Breast Carcinoma, Colon Carcinoma, Esophageal Carcinoma, Gastric Carcinoma, Head and Neck Carcinoma, Kidney Carcinoma, Lung Carcinoma, Ovarian Carcinoma, Pancreatic Carcinoma, Solid Neoplasm, Uterine Corpus Cancer
- Interventions
- Computed Tomography, Gallium Ga 68 FAPi-46, Gallium Ga 68-labeled PSMA-11, Positron Emission Tomography, 18F-FDG
- Procedure · Radiation
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2031
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Chronic Diseases in Children
- Interventions
- Food Navigation
- Behavioral
- Lead sponsor
- Parkland Health and Hospital System
- Other
- Eligibility
- 8 Years to 15 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Non Small Cell Lung Cancer, Metastatic NSCLC, Recurrent Non Small Cell Lung Cancer
- Interventions
- Pembrolizumab, GT103
- Drug
- Lead sponsor
- Ryan Dackor
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 6
- States / cities
- Chicago, Illinois • Indianapolis, Indiana • Detroit, Michigan + 3 more
- Conditions
- Neurodevelopmental Disorders
- Interventions
- MOCHA
- Device
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 5 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Facial Rhytides, Crow's Feet Lines, Glabellar Lines, Nasolabial Fold
- Interventions
- onabotulinumtoxinA, bimatoprost ophthalmic solution 0.03%, JUVÉDERM® ULTRA XC, JUVÉDERM® ULTRA PLUS XC, JUVÉDERM® VOLUMA® XC
- Biological · Drug · Device
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 35 Years to 65 Years
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Hypoxic Ischemic Encephalopathy of Newborn, Hypoxic Ischemic Encephalopathy, Hypoxic Ischemic Encephalopathy (HIE)
- Interventions
- Genome sequencing
- Genetic
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 0 Days to 1 Year
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Breast Cancer
- Interventions
- cytology specimen collection procedure
- Other
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2027
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- COVID-19, SARS-CoV2
- Interventions
- Bamlanivimab, Placebo, Etesevimab
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Bentonville, Arkansas + 23 more
- Conditions
- Waldenstrom Macroglobulinemia
- Interventions
- Pirtobrutinib, Mosunetuzumab
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2035
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Severe Hypertension, Hypertension
- Interventions
- Emergency Department-Initiated Team-Based Care, Usual Care
- Other
- Lead sponsor
- Henry Ford Health System
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 4
- States / cities
- Dearborn, Michigan • Detroit, Michigan • Wyandotte, Michigan
- Conditions
- Decision Making, Cognition, Mental Simulation, Problem Solving, Planning
- Interventions
- Four-in-a-Row Task
- Behavioral
- Lead sponsor
- New York University
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Schizophrenia
- Interventions
- armodafinil, placebo
- Drug
- Lead sponsor
- Cephalon
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 287 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 39
- States / cities
- Little Rock, Arkansas • Anaheim, California • Escondido, California + 32 more
- Conditions
- Hereditary Spastic Paraplegia, SPG47, SPG50, SPG51, SPG52, AP4-related Hereditary Spastic Paraplegia, Early Onset Hereditary Spastic Paraplegia, SPG4, SPG3A, SPG15, SPG11
- Interventions
- Not listed
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- Up to 30 Years
- Enrollment
- 700 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2030
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- CART-PSMA-TGFβRDN, Cyclophosphamide, Fludarabine, Anakinra
- Biological · Drug
- Lead sponsor
- Tceleron Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 9
- States / cities
- Tampa, Florida • Kansas City, Kansas • St Louis, Missouri + 5 more
- Conditions
- HIV
- Interventions
- E/C/F/TAF
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 4
- States / cities
- Tampa, Florida • Detroit, Michigan • New York, New York + 1 more
- Conditions
- Wet Macular Degeneration
- Interventions
- Faricimab, Aflibercept, Sham Procedure
- Drug · Procedure
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 658 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 41
- States / cities
- Phoenix, Arizona • Mountain View, California • Sacramento, California + 36 more
- Conditions
- Acute-graft-versus-host Disease, Chronic Graft-versus-host-disease, Solid Organ Transplant
- Interventions
- Ruxolitinib
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Mid-facial Volume Deficit Related to Aging
- Interventions
- Juvéderm® VOLUMA XC
- Device
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 35 Years to 65 Years
- Enrollment
- 345 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Endometrial Cancer, ARID1A Gene Mutation, Recurrent Endometrial Carcinoma
- Interventions
- Avelumab, M1774
- Drug
- Lead sponsor
- Panagiotis Konstantinopoulos, MD, PhD
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Respiratory Syncytial Virus, Human Metapneumovirus
- Interventions
- mRNA-1345, mRNA-1365, Placebo, Nimenrix
- Biological · Drug
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 5 Months to 24 Months
- Enrollment
- 186 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Melrose Park, Illinois + 8 more